PharVision Advisers’s ATRenew RERE Stock Holding History

PharVision Advisers’s Portfolio RERE Stock Details RERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,111	Closed	-$112K	–	528
2025 Q4	$112K	Buy	+21,111	New	+$94.6K	0.06%	646

Other funds holding RERE

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

YCM

Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return

PGCM

Prescott Group Capital Management Tulsa, Oklahoma $1.16B AUM 53.61% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

TPC

Tiger Pacific Capital New York $410M AUM 0.97% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's RERE Position: Q1 2026 in Review

PharVision Advisers sold out of ATRenew (RERE) in Q1 2026, closing a stake of 21,111 shares — an estimated $112K sold.

PharVision Advisers first reported a position in RERE in Q4 2025 and held it in 1 quarter. The position peaked at $112K in Q4 2025. 82 funds tracked by Wall St. Rank hold RERE as of Q1 2026.

PharVision Advisers reported no remaining ATRenew position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 21,111 ATRenew shares in Q1 2026, an estimated $112K.
PharVision Advisers first reported a position in ATRenew in Q4 2025 and held it in 1 quarter.
PharVision Advisers's ATRenew position peaked at $112K in Q4 2025.
82 funds tracked by Wall St. Rank held ATRenew as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.